SanofiMEX:SAN1N 72 Pretax Margin % is 10.22% as of Dec. 2025, which is 33% below its 10-year median of 15.20. GuruFocus rates MEX:SAN1N with a GF Score™ of 72/100 and a GF Value™ of MXN2,212.65 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Sanofi ranks better than 65.55% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Sanofi's Pre-Tax Income for the
six
months ended in Dec. 2025 was MXN54,671 Mil. Sanofi's Revenue for the
six
months ended in Dec. 2025 was MXN535,005 Mil. Therefore, Sanofi's pretax margin for the quarter that ended in Dec. 2025 was 10.22%.
The historical rank and industry rank for Sanofi's Pretax Margin % or its related term are showing as below:
MEX:SAN1N'
s Pretax Margin % Range Over the Past 10 Years
Min: 7.31 Med: 15.2 Max: 36.87
Current: 13.22
MEX:SAN1N's Pretax Margin % is ranked better than 65.55% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs MEX:SAN1N: 13.22
Sanofi (MEX:SAN1N) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sanofi Pretax Margin % Related Terms
Sanofi Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Sanofi's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SAN1N vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Sanofi's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sanofi's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi (MEX:SAN1N) has a Pretax Margin % of 10.22% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sanofi and its competitors. This is 33% below median its historical median of 15.20. Over the past decade, Sanofi's Pretax Margin % has ranged from 7.31 to 36.87. According to the industry distribution chart, Sanofi ranks #329 out of 955 companies in the Drug Manufacturers industry, placing it in the top 34.5%.
Is Sanofi's Pretax Margin % too high?
Sanofi's current Pretax Margin % of 10.22% is 33% below median its 10-year median of 15.20. Over the past 10 years, this metric has ranged from a low of 7.31 to a high of 36.87. The Drug Manufacturers industry median Pretax Margin % is 7.28. Sanofi's value of 10.22% is 40.4% above this industry median. Based on the distribution chart, Sanofi ranks #329 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanofi has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #329 out of 955 companies for Pretax Margin %. This puts Sanofi in the upper half of its industry. The industry median Pretax Margin % is 7.28. Sanofi's value of 10.22% is 40.4% above this benchmark. Historically, Sanofi's own Pretax Margin % has ranged from 7.31 to 36.87 over the past decade. While the company's 10-year median is 15.20 vs. the industry median of 7.28, Sanofi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi's current Pretax Margin % of 10.22% is 40.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current Pretax Margin % is 10.22%, which is 33% below median its own 10-year median of 15.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (MEX:SAN1N) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,212.65, compared to a current price of MXN1,525.85 — trading 31% below its estimated fair value. The current Pretax Margin % is 10.22%, which is 33% below median its 10-year median of 15.20 and 40.4% above the Drug Manufacturers industry median of 7.28. Sanofi's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sanofi (MEX:SAN1N), the current Pretax Margin % is 10.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (MEX:SAN1N) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of MXN1,525.85 is trading 31% below its estimated GF Value™ of MXN2,212.65.
GuruFocus considers Sanofi to be Possible Value Trap.
Key valuation signals for MEX:SAN1N:
Pretax Margin %: 10.22% (33% below median its 10-year median of 15.20)
GF Value™: MXN2,212.65 vs. price of MXN1,525.85 (31% below fair value)
Industry Position: 40.4% above the Drug Manufacturers median (#329 of 955)
No single metric tells the full story. See the MEX:SAN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
72GF Score
Get the complete analysis for MEX:SAN1N
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SAN1N has been successfully added to your 
